Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

age clinical studies," said Mr. Swisher.

Actions taken today will allow the company to direct most of its resources into the late-stage development of voreloxin. Sunesis expects this realignment of personnel and programs to reduce annual operating expenses by more than $15 million, thus enabling increased investment into such development. Current burn rate guidance for the second half of 2008 is in the range of $12-15 million, including payment of severance and other restructuring charges.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication- dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Statistics released from a number of organizations ... during the holidays, beginning with Thanksgiving eve, which is ... The data, highlighted in an Infographic ... of their annual Sober Days for the Holidays ... drinking and increased rates of DUI injuries and deaths ...
(Date:11/21/2014)... Mass. , Nov. 21, 2014  Alere Inc. ... rapid diagnostic tests, has appointed Juliet Cunningham ... role, Cunningham will be responsible for driving communications with ... execute on a series of changes to increase shareholder ... progress to investors," said Namal Nawana, Chief Executive Officer. ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
Breaking Medicine Technology:Alarming Stats Show Holiday Drinking an Issue for Many 2Alere Appoints Juliet Cunningham to Lead Investor Relations 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4
... than 60,000 young children end up in emergency rooms ... or caregivers were not looking. To remind parents and ... Centers for Disease Control and Prevention (CDC) and the ... with the PROTECT Initiative , today launched the ...
... 2011 Sotera Wireless, Inc. today announced the completion ... Singapore-based global fund, EDBI. The round also included new ... Ventures, Intel Capital and West Health Investment Fund. The ... with Cerner, a leading health care technology company, which ...
Cached Medicine Technology:CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 2CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 3Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner 2
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has ... . They are now offered at deeply discounted prices, ... from now to Dec. 15. The main purpose of the ... company’s high quality items are ideal options for ladies who ... of money. All its new mint cocktail dresses are very ...
(Date:11/23/2014)... TX (PRWEB) November 23, 2014 ... Devices Market 2006 to 2020 - Asia-Pacific” provides ... energy devices market segments: minimally invasive body contouring ... devices. The analysis includes market size data by ... for the following countries: China, Japan, South Korea, ...
(Date:11/23/2014)... 2014 Pro Ace Care, a renowned Vancouver ... now be providing an 8 year warranty on its selected ... installations went up due to the impending winter season, it ... of the premium service that the company provides. As a ... on John Wood and Bradford hot water tanks. , ...
(Date:11/23/2014)... (HealthDay News) -- Close friends have more influence on ... a new study says. "We,ve known for ... influence on individual alcohol use, but there are no ... and the friend group,s influence on those decisions," Jonathon ... Public Health, said in a university news release. ...
(Date:11/23/2014)... a notable magnetic locks maker, has released a variety ... available at low rates up to 30% off. ... emergency doors. The emergency door adopts fireproof material and ... colors. All of the products are top-quality guaranteed. ... as easy as many people think. As a ...
Breaking Medicine News(10 mins):Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Close Friends May Be Key to Teens' Drinking 2
... WuXi PharmaTech (Cayman) Inc.,(NYSE: WX ), a ... company with operations in China and the,United States, today ... to,the WuXi PharmaTech Board of Directors. , ... Dr. Ge Li, WuXi,s Chairman and ...
... Tenn., Feb. 5 Brookdale Senior Living Inc. (NYSE: ... Chief Executive Officer, and Mark Ohlendorf, Co-President and Chief ... at the UBS Global Healthcare Services Conference in New ... at 8:30 a.m. Eastern Time.The presentation is being audio ...
... WASHINGTON, Feb. 5 The following statement of ... was released today:(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The smoke-free restaurant ... all workers and the public from the proven ... Virginia House and Senate to reject this bill ...
... 5, 2009 Narcotics have an irreversible effect on ... according to Dr. Stphane Potvin of the Universit de ... Lafontaine Hospital. , According to his research, some ... from drug addiction. The study has shown that drug ...
... 5 The following is a statement in response ... Bader Ginsburg being diagnosed with pancreatic cancer from Julie ... Network, the only national organization creating hope in a ... advocacy for a cure. "Our thoughts are with ...
... 5 /PRNewswire/ -- As the strain of ... Quorum Health Resources (QHR) has announced the launch of ... subsidiary that provides hospitals and health systems with short-term, ... challenges are great, according to the American Hospital Association,s ...
Cached Medicine News:Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 2Health News:WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board 3Health News:Virginia Leaders Should Reject Flawed Smoke-Free Legislation That Fails to Protect Everyone's Right to Breathe Clean Air 2Health News:Early Detection Methods for Pancreatic Cancer Urgently Needed: A Statement From the Pancreatic Cancer Action Network 2Health News:Intensive Resource Group (IRG) Helps Hospitals Address Financial and Operational Crisis 2Health News:Intensive Resource Group (IRG) Helps Hospitals Address Financial and Operational Crisis 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: